Skip to main content

Table 2 Treatment-related adverse events that occurred in at least one of the enrolled patients

From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

Event All grade-no.(%) Grade 3–4-no.(%)
Neutrophil count decreased 21(30) 5 (7)
Platelet count decreased 23 (33) 5 (7)
Anemia 12 (17) 2 (2)
Alopecia 2 (2) /
Diarrhea 1 (1) /
Nausea 8 (12) 2 (2)
Vomiting 5 (7) 2 (2)